{"id":"NCT02449239","sponsor":"Sesen Bio, Inc.","briefTitle":"Vicinium Treatment for Subjects With Non-muscle Invasive Bladder Cancer Previously Treated With BCG","officialTitle":"Open-Label, Multicenter, Ph 3 [Phase 3] Study to Evaluate the Efficacy and Tolerability of Intravesical Viciniumâ„¢ in Subjects With Non Muscle-Invasive Carcinoma in Situ and/or High-Grade Papillary Disease of the Bladder Treated With BCG","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-08","primaryCompletion":"2020-05","completion":"2022-05","firstPosted":"2015-05-20","resultsPosted":"2023-07-24","lastUpdate":"2023-07-24"},"enrollment":133,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Bladder Cancer"],"interventions":[{"type":"BIOLOGICAL","name":"Vicinium","otherNames":["VB4-845","Oportuzumab monatox"]}],"arms":[{"label":"Vicinium","type":"EXPERIMENTAL"}],"summary":"Because of the high risk for development of muscle invasive disease, cystectomy is recommended for CIS, high-grade Ta and T1 patients who experience disease recurrence following intravesical therapy. Vicinium is an experimental agent that may provide an alternative to cystectomy","primaryOutcome":{"measure":"Complete Response Rate at 3 Months","timeFrame":"3 months from start of treatment","effectByArm":[{"arm":"Vicinium","deltaMin":39,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":70,"countries":["United States","Canada"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":21,"n":133},"commonTop":["Urinary tract infection","Dysuria","Haematuria","Micturition urgency","Pollakiuria"]}}